Diabetes Mellitus Type 2DHS2NCT07642830
Digital Health Solutions for Patients With Type 2 Diabetes
A study testing CGM in people with Diabetes Mellitus Type 2, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
Trial summary
We will conduct a prospective, single-center observational study involving 60 adult T2D patients recruited from Chang Gung Memorial Hospital. Participants will be randomly allocated to either a CGM group or a control group receiving standard care. Read more about this study
- Who is it for?
- Ages 20 to 75 years
- Conditions the study is for
- Diabetes Mellitus Type 2
- What is being tested?
- CGM
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteTaiwan
- Study dates
- 28 May 2026to 4 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with confirmed diagnosis of T2D for >1 year, capable of using a smartphone, and willing to sign informed consent.
Who cannot join
- Patients with severe cardiac, hepatic, or renal disease; pregnant women; those participating in other experimental treatments; or unable to follow up.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Clinical Research of Digital Health Solutions for Patients With Type 2 Diabetes
We will conduct a prospective, single-center observational study involving 60 adult T2D patients recruited from Chang Gung Memorial Hospital. Participants will be randomly allocated to either a CGM group or a control group receiving standard care. The intervention group will utilize mobile apps for medication tracking, and a remote communication platform. All participants will collect clinical data-including HbA1c, Time in Range (TIR), insulin use-at baseline and 12 weeks. Patient adherence and satisfaction with CGM will also be assessed.
- Conditions
- Diabetes Mellitus Type 2
- Being tested
- CGM
- Keywords
- Type 2 Diabetes, Digital Health, Continuous Glucose Monitoring
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CGMDevice
Use CGM in the glucose monitoring for CGM arm
| Study group | Role | What they receive |
|---|---|---|
| CGM | Experimental | CGM use in this arm Receives: Device: CGM |
| Control | No intervention | Standard care |
What is being measured
The primary outcome is the main question the study is designed to answer.
HbA1c
Change in HbA1c
Measured: From baseline to week 12
TIR
Improvement in Time in Range
Measured: From baseline to week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2026
- Study start28 May 2026 (estimated)
- Primary completion4 Jan 2027 (estimated)
- Study completion4 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus Type 2Studies of the same condition, open and under way.
- More trials run by Chang Gung Memorial HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chang Gung Memorial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, CHIA-HUNG LIN, Chang Gung Memorial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07642830
- Sponsor's protocol ID
- 202501413B0
- Acronym
- DHS2
- Status last verified
- Jun 2026
- First submitted
- 8 Jun 2026
- Last updated
- 11 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Research of Digital Health Solutions for Patients With Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT07642830
- Acronym / sponsor ID
- DHS2 / 202501413B0
- Conditions
- Diabetes Mellitus Type 2
- Keywords
- Type 2 Diabetes, Digital Health, Continuous Glucose Monitoring
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Chang Gung Memorial HospitalUniversity, hospital or other
- Study start
- 28 May 2026 (estimated)
- Primary completion
- 4 Jan 2027 (estimated)
- Study completion
- 4 Jan 2027 (estimated)
- First posted
- 11 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We will conduct a prospective, single-center observational study involving 60 adult T2D patients recruited from Chang Gung Memorial Hospital. Participants will be randomly allocated to either a CGM group or a control group receiving standard care. The intervention group will utilize mobile apps for medication tracking, and a remote communication platform. All participants will collect clinical data-including HbA1c, Time in Range (TIR), insulin use-at baseline and 12 weeks. Patient adherence and satisfaction with CGM will also be assessed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CGM | Experimental | Device: CGMCGM use in this arm |
| Control | No intervention | –Standard care |
Who may qualify
- Ages
- 20 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with confirmed diagnosis of T2D for >1 year, capable of using a smartphone, and willing to sign informed consent.
Key exclusion criteria (1 listed)
- Patients with severe cardiac, hepatic, or renal disease; pregnant women; those participating in other experimental treatments; or unable to follow up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CGMUse CGM in the glucose monitoring for CGM arm | Device | CGM |
Primary outcome
HbA1c
Time frame: From baseline to week 12
Change in HbA1c
TIR
Time frame: From baseline to week 12
Improvement in Time in Range
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Diabetes Mellitus Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CGM in people with Diabetes Mellitus Type 2, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HbA1c (time frame: From baseline to week 12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.